Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Environmental DNA (eDNA) sampling is prone to both false-positive and false-negative errors. We review statistical methods to account for such errors in the analysis of eDNA data and use simulations to compare the performance of different modelling approaches. Our simulations illustrate that even low false-positive rates can produce biased estimates of occupancy and detectability. We further show that removing or classifying single PCR detections in an ad hoc manner under the suspicion that such records represent false positives, as sometimes advocated in the eDNA literature, also results in biased estimation of occupancy, detectability and false-positive rates. We advocate alternative approaches to account for false-positive errors that rely on prior information, or the collection of ancillary detection data at a subset of sites using a sampling method that is not prone to false-positive errors. We illustrate the advantages of these approaches over ad hoc classifications of detections and provide practical advice and code for fitting these models in maximum likelihood and Bayesian frameworks. Given the severe bias induced by false-negative and false-positive errors, the methods presented here should be more routinely adopted in eDNA studies.

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-0998.12486DOI Listing

Publication Analysis

Top Keywords

false-positive errors
16
approaches account
8
account false-positive
8
environmental dna
8
prone false-positive
8
false-positive rates
8
occupancy detectability
8
false-positive
7
errors
6
statistical approaches
4

Similar Publications

Accurate genetic evaluations rely on high-quality phenotypic data; however, measurement errors and data inconsistencies-such as those arising from unsupervised or incomplete sources-pose challenges to their reliability. This study investigates the effect of response errors on genetic evaluations across continuous and categorical traits. We introduce an additive measurement error model to illustrate how phenotypic errors influence genetic effects and variance estimation.

View Article and Find Full Text PDF

Introduction: Vaccination against COVID-19 has generated a dramatic reduction in deaths and infections worldwide. However, there may be cross-reactivity with numerous biochemical and immunological markers. The Widal test for the detection of typhoid fever is an antigen-antibody test that can be affected by vaccination, causing errors in the results, so we determined the frequency of false positive results of the Widal test in adults vaccinated with Commirnaty (Pfizer -BioNtech) and BBIBP-CorV (Sinopharm) vaccines.

View Article and Find Full Text PDF

Purpose: Experimental patient-specific quality assurance (PSQA) in proton therapy is a labor-intensive process requiring physical access to treatment rooms, beam time, and significant human resources. With the increasing complexity of treatment plans and the implementation of adaptive therapy, the need for efficient alternatives is pressing. Simulation-based techniques are proposed as a replacement or enhancement for experimental ones.

View Article and Find Full Text PDF

Commentary and Review on Prospective Prediction of Bioequivalence of Oral Dosage Forms using Compendial Dissolution Testing and PBPK Modeling.

AAPS J

September 2025

Pharmaceutical Science, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut, 06340, USA.

A virtual bioequivalence (VBE) approach utilizing physiologically based pharmacokinetic (PBPK) modeling presents a compelling alternative for pharmaceutical industries. This method can significantly reduce the time and cost associated with clinical bioequivalence (BE) trials while minimizing the risk of detecting a type II error (a false negative), as well as a type I error (a false positive). Additionally, it aligns with ethical considerations by obviating the need to expose healthy volunteers to investigational drugs.

View Article and Find Full Text PDF

Lung cancer continues to be the leading cause of cancer-related mortality, with cytologic samples often serving as the primary diagnostic tool. However, differentiating between benign and malignant processes in lung cytology can be difficult because various non-neoplastic conditions closely resemble malignant lesions, which may lead to misdiagnosis. This review offers nine essential tips to help cytopathologists prevent false-positive diagnoses of malignancy in non-neoplastic processes.

View Article and Find Full Text PDF